SEC Tracker
Get the app

Maze Therapeutics MAZE

Maze Therapeutics Q1 FY25: net loss $32.8M; diluted EPS −$1.15

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Maze Therapeutics reported for Q1 FY25, the quarter ended Mar 31, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$32.8MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Diluted EPS−$1.15No year-earlier figure tagged10-Q income statement, on EDGAR
  3. Cash and cash equivalents$294.4MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  4. Cash from operations−$29.5MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Maze Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Theravance Biopharma TBPH public float $449M, Jun 30, 2025
  2. Zevra Therapeutics ZVRA public float $455M, Jun 30, 2025
  3. aTYR PHARMA ATYR public float $464M, Jun 30, 2025
  4. Arvinas ARVN public float $469M, Jun 30, 2025
  5. CytoDyn CYDY public float $418M, Nov 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.